Pharmacia Axert Is First Of Triptan 2nd Wave; Chest Pain "Infrequent" – Label
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The 17-month FDA review period for Pharmacia's Axert (almotriptan) makes it the quickest product to clear FDA among the second wave of triptans pending at the agency.